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Background: Excessive generation of radical oxygen species (ROS) is a contributor to 
skin pathologies. Resveratrol (RSV) is a potent antioxidant. Solid lipid nanoparticles (SLN) 
and nanostructured lipid carriers (NLC) can ensure close contact and increase the amount of 
drug absorbed into the skin. In this study, RSV was loaded into SLN and NLC for dermal 
applications.
Methods: Nanoparticles were prepared by high shear homogenization using Compritol 888ATO, 
Myglyol, Poloxamer188, and Tween80. Particle size (PS), polydispersity index (PI), zeta   potential 
(ZP), drug entrapment efficiency (EE), and production yield were   determined. Differential 
scanning calorimetry (DSC) analysis and morphological transmission   electron microscopy 
(TEM) examination were conducted. RSV concentration was optimized with cytotoxicity studies, 
and net intracellular accumulation of ROS was monitored with cytofluorimetry. The amount of 
RSV was determined from different layers of rat abdominal skin.
Results: PS of uniform RSV-SLN and RSV-NLC were determined as 287.2 nm ± 5.1 and 
110.5 nm ± 1.3, respectively. ZP was −15.3 mV ± 0.4 and −13.8 mV ± 0.1 in the same order. 
The drug EE was 18% higher in NLC systems. TEM studies showed that the drug in the shell 
model was relevant for SLN, and that the melting point of the lipid in NLC was slightly lower. 
Concentrations below 50 µM were determined as suitable RSV concentrations for both SLN 
and NLC in cell culture studies. RSV-NLC showed less fluorescence, indicating less ROS 
production in cytofluorometric studies. Ex vivo skin studies revealed that NLC are more efficient 
in carrying RSV to the epidermis.
Conclusion: This study suggests that both of the lipid nanoparticles had antioxidant properties 
at a concentration of 50 µM. When the two systems were compared, NLC penetrated deeper 
into the skin. RSV-loaded NLC with smaller PS and higher drug loading appears to be superior 
to SLN for dermal applications.
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Introduction
Reactive oxygen species (ROS) are generated as by-products of cellular metabolism, 
primarily in mitochondria. When their production exceeds the cell’s antioxidant 
capacity, macromolecules such as lipids, proteins, and DNA can be damaged.1 
Excessive generation of ROS in the skin is believed to be an important contributor to 
a variety of cutaneous pathologies, including different types of cancers.2,3 ROS such 
as superoxide anion, hydrogen peroxide, and singlet oxygen, also play a critical role 
in many pathological conditions, including immune suppression, photo-aging, and 
photocarcinogenesis.4–6 Using antioxidants as a therapeutic approach to overcome the 
occurrence of these pathologies appears promising.
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Resveratrol (RSV) (trans-3,4,5-trihydroxystilbene), 
a phytoalexin found in grapes, nuts, fruits, and red wine, 
is a potent antioxidant with strong anti-inflammatory and 
antiproliferative properties.7 RSV induces promyelocytic 
leukemia cell differentiation, and exhibits anticancer 
properties by mediating apoptosis, arresting cell cycle 
progression, antiproliferation and inhibiting ribonucleotide 
reductase, ornithine decarboxylase, and cyclooxygenase 
through modulation of prostaglandin production.8
Since their first description, solid lipid nanoparticles 
(SLNs) have attracted increasing attention as an efficient and 
nontoxic alternative lipophilic colloidal drug carrier, prepared 
either with physiological lipids or lipid molecules used as 
common pharmaceutical excipients. SLNs were developed 
in the early 1990s as an alternative carrier system to other 
colloidal formulations such as emulsions, liposomes, and 
polymeric nanoparticles. SLNs are produced by replacing the 
liquid lipid (oil) component of an oil/water emulsion with 
lipids that are solid at both room and body temperature.9 In 
the second generation of lipid nanoparticle technology, the 
particles are produced using blends of solid lipids and oils – 
so-called nanostructured lipid carriers (NLCs).10
These lipid nanoparticles have many features that 
are advantageous for dermal application and can provide 
controlled release profiles.11–13 They can be built from 
physiological and biodegradable lipids with generally 
recognized as safe (GRAS) status.9,10 The irritant potential 
for skin and eyes as well as cytotoxicity for normal human 
keratinocytes is low.14 The small size ensures close contact 
with the stratum corneum, and can increase the amount of 
drug absorbed by the skin. Lipid nanoparticles are also able 
to enhance the chemical stability of compounds sensitive to 
light, oxidation, and hydrolysis.15–19
The cellular uptake of RSV-loaded SLN and its beneficial 
effects on cellular fate has been evidenced recently in a cell 
culture study.20 There does not, however, appear to be published 
comparative data available regarding the antioxidant effects 
of RSV-loaded SLNs and NLCs for dermal applications. The 
primary aim of this study was to design RSV-loaded SLNs and 
NLCs. The second aim was to evaluate the cytotoxicity and 
antioxidant capacity of SLNs and NLCs by determining the 
amount of ROS produced in fibroblasts, and the third aim was to 
evaluate the accumulation of RSV in different layers of skin.
Materials and methods
Materials
Compritol® 888 ATO (Glyceryl behenate) was generously 
supplied by Gattefossée (Nanterre, France). Poloxamer® 
188 (Pluronic F68) was kindly donated by BASF (Ludwig-
shafen, Germany). Tween® 80 (Polysorbate 80) and RSV were 
obtained from Sigma Aldrich (Milan, Italy). Miglyol® 812 
was purchased from Caelo (Hilden, Germany).
All high performance liquid chromatography (HPLC) 
reagents were purchased from Sigma Aldrich. The other 
chemicals were obtained from Carlo Erba (Milan, Italy). All 
filters were purchased from Sartorius AG (Milan, Italy).
Preparation of RSV-loaded SLNs  
and NLCs
RSV-loaded SLNs and NLCs were prepared by the high 
shear homogenization method.21 The lipid phase – Compritol 
888 ATO (C888) and 5 mg RSV – and the aqueous phase: 
150 mg of Poloxamer 188 (P188) and 75 mg of Tween 80 
(Tw 80) in 12.5 mL bidistilled water, were heated to 85°C, 
separately. The aqueous phase was poured into the lipid 
phase, at a stirring speed of 24,000 rpm with UltraTurrax 
(T25). The particles were dispersed in bidistilled water and 
kept at −20°C for 10 minutes. Blank SLNs were prepared 
in a similar way, without the drug. Different lipid-to-drug 
ratios have been studied to evaluate their effect on physical 
properties, as seen in Table 1. After determination of the 
optimum lipid-to-drug concentration, NLCs were prepared 
using the same method, by replacing 5%, 15%, 30%, and 
45% of the solid lipid with liquid Miglyol oil.
Measurement of particle size  
and polydispersity index
Particle size (PS) and polydispersity index (PI) were 
measured at 25°C using Photon Correlation Spectroscopy 
Table 1 The formulation parameters of produced SLNs and NLC
Code The amount (mg) employed/25 mL of dispersion
C 888 Miglyol P 188 Tw 80 RSV
S1 100 – 50 25 –
RS1 100 – 50 25 1
RS2 100 – 50 25 10
RS3 300 – 50 25 10
RS4 300 – 150 75 10
N1 285 15 150 75 –
N2 255 45 150 75 –
N3 210 90 150 75 –
N4 165 135 150 75 –
RN1 285 15 150 75 10
RN2 255 45 150 75 10
RN3 210 90 150 75 10
RN4 165 135 150 75 10
Abbreviations: NLC, nanostructured lipid carriers; RSV, resveratrol; SLNs, solid 
lipid nanoparticles; Tw, Tween.
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(Zetasizer Nano ZS; Malvern, Milan, Italy) at an angle of 
173° after dilution of formulations with bidistilled and filtered 
(0.45 µm) water. Each sample was measured in triplicate.
Measurement of zeta potential
The zeta potential (ZP) of SLN and NLC dispersions was 
measured at 25°C, under an electrical field of 40 V/cm 
(Zetasizer Nano ZS; Malvern). The measurements were 
conducted in triplicate.
Drug entrapment efficiency
In order to determine drug entrapment efficiency (EE), one 
end of the dialysis bag (cutoff 25 kDa) was tied, and the SLN 
or NLC dispersion was placed in the bag. The other opening 
of the bag was then closed. These bags were then placed in 
a centrifuge tube and the tube was filled with a mixture of 
ethanol and water (at a 1:1 ratio) and centrifuged for 1 hour 
at 14,000 rpm. The mixture of ethanol and water was then 
analyzed for RSV content by HPLC, allowing the quantity 
of free drug to be determined. The encapsulated amount of 
RSV was calculated by subtracting the free amount of RSV 
from the total amount present in the dispersion. Each batch 
was evaluated three times. The EE percentage was calculated 
by the following equation where Wi is the amount of initial 
drug and Wf is the amount of free drug:
  ΕΕ%=
− Wi Wf
Wi
× 100   (1)
The HPLC system (Agilent Series 1100; Data Apex, 
Milan, Italy) consists of a 25-cm long, 4-mm inner diameter 
stainless C18 column (ACE) and a mobile phase of methanol, 
water, and acetic acid (52:48:0.05 v/v/v). The flow rate and UV 
wavelength were set at 1 mL/min and 303 nm, respectively.
Lyophilization and the determination  
of production yield
Five milliliters of the SLN formulation was placed in 10 mL 
glass vials, without any cryoprotective agent. The samples 
were slowly frozen over 12 hours, and pre-cooled to −80°C. 
Lyophilization was performed at a pressure of 0.07 millibars 
for 24 hours at −45°C using a Christ Alpha 1-2 LD Freeze 
Dryer (Martin Christ Gefriertrocknungsanlagen GmbH, 
Hannover, Germany).
The production yield was calculated from the solid 
amount obtained from the lyophilization of SLNs, with the 
following equation:
  Y% = [(WT–WL)/WT] × 100  (2)
where WT is the theoretical amount and WL is the 
lyophilizate amount.
Differential scanning calorimetry analysis
Differential scanning calorimetry (DSC) analysis was 
  performed, with the samples sealed in aluminum pans under 
a nitrogen air atmosphere, at a flow rate of 20 mL/min 
and evaluated in 30°C–300°C temperature ranges (DSC 
8000; Perkin Elmer, Milan, Italy). RSV , C 888, a physical 
mixture of C 888:RSV and SLN, and NLC formulation were 
evaluated.
Transmission electron microscopy (TEM) 
analysis
Morphological examination of the SLN and NLC was 
performed with a transmission electron microscope (CM12 
Philips, Amsterdam, the Netherlands). The samples were 
stained with 2% (w/v) phosphotungstic acid and placed on 
copper grids for viewing by TEM.
Cell culture studies
Cytotoxicity studies
Normal Human Dermal Fibroblasts (NHDF) from juvenile 
foreskins (PromoCell GmbH, Heidelberg, Germany) were 
used. Cells between the 2nd and 5th passage were used for 
all experiments. Fibroblasts were grown in the presence 
of Dulbecco’s modified Eagle medium (DMEM; Sigma) 
and supplemented with 10% fetal calf serum (FCS; Sigma) 
with 200 IU/mL penicillin, and with 0.2 mg/mL strepto-
mycin and kept at 37°C in a 5% CO2 atmosphere with 95% 
relative humidity.
Fibroblasts were seeded in each well of 96-well plates 
(area of 0.34 cm2) at a density of 105 cells/cm2. Cells were 
grown over 24 hours until their spatial arrangement was 
subconfluent. After 24 hours, the medium was replaced with a 
sample; in particular, the cells were put in contact with RSV-
loaded SLN and NLC, and RSV alone at the following RSV 
concentrations: 10 µM, 25 µM, 50 µM, 100 µM, 250 µM, 
and 500 µM. Cell substrates were incubated for 24 hours. 
Subsequently, the medium was removed and the WST-1 
(water soluble tetrazolium) test was performed. The WST-1 
test is based on the activity of mitochondrial dehydrogenases 
of vital cells that convert WST-1 in a water soluble formazan. 
For this purpose, 100 µL of WST-1 solution (Roche 
Diagnostic, Milan, Italy) at 10% (v/v) in HBSS (Hank’s 
Buffered Salt Solution) pH 7.4 was put in contact with each 
cell substrate for 3 hours. The absorbance of each well was 
assayed by means of an ELISA plate reader at 490 nm with 
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a reference of 655 nm.22 Cell viability was calculated as a 
percentage ratio between the absorbance of each sample and 
the absorbance of complete growth medium.
Cytofluorimetry studies
To monitor net intracellular accumulation of ROS, the fluores-
cent probe DCFH-DA (2,7-dichlorfluoresceine acetate) was 
used. Fibroblasts were seeded in each well of a 12-well culture 
plate (with an area of 3.8 cm2) at a density of 105 cells/cm2. 
Cells were grown over 48 hours until their spatial arrange-
ment was subconfluent, and were then put in contact with 
RSV-loaded SLN, RSV-loaded NLC, and RSV alone at 
50 µM of RSV concentration. After 4 hours of contact, H2O2 
at a concentration of 1.5 mM was added to each well. Cell 
substrates were then incubated for 24 hours. DCFH-DA at 
a concentration of 1 mM was put in contact with the cell 
substrates for 15 minutes.23 Cells were then scraped from the 
bottom of each well and a cell suspension was obtained.
This suspension was then centrifuged at 1500 rpm for 
5 minutes and the supernatant was removed. The cell pel-
let was then resuspended in 500 µL of phosphate buffered 
saline (PBS). Each cell suspension was assayed by means 
of a cytofluorimeter (Navios Flow Cytometer; Beckman 
Coulter, Inc, Milan, Italy) using an excitation wavelength of 
488 nm, and the emission was then evaluated at a wavelength 
of 525 nm. The data collected were analyzed by means of 
Kaluza® Analysis software (v 1.2; Beckman Coulter, Inc). 
The results obtained for the cell substrates put in contact with 
H2O2 resulted in maximum oxidative damage (100%).
Ex vivo diffusion studies
Rat abdominal skin was excised immediately after the animal 
sacrifice, and purified from the surrounding tissue. The 
skin was placed in a Franz diffusion cell and 200 µL of the 
formulations was evaluated. The receptor phase consisted of 
ethanol and water at a ratio of 1:1 at 37°C and sink conditions 
were taken into consideration. The formulations to be tested 
were kept in contact with the tissue for 24 hours, and at 
certain time intervals, the RSV amount was determined in 
the samples taken from the receptor phase.
After 24 hours, the skin samples were taken, the excess 
formulation removed, and the skin surface cleaned with dry 
paper. The epidermis was separated from the dermis by means 
of heat application.24 The tissue samples were homogenized 
using an Ultra-Turrax (IKA, Guangzhou, China) at 8000 rpm 
for 10 minutes (in 2 mL of ethanol) and the accumulated 
amount of RSV in the skin was extracted with the aid of a 
horizontal shaker for an additional 24 hours.
Statistical analysis
Statistical differences were determined using analysis of 
variance (ANOVA), followed by Tukey’s test for compari-
sons between groups. The significance level was taken as 
95% (P , 0.05).
Results and discussion
Preparation of RSV-loaded SLNs  
and NLCs
The particle size values were evaluated to understand the 
effect of the lipid-to-drug ratio on the physical properties of 
SLN as shown in Table 2.
It was observed that larger nanoparticles could be 
obtained with the increment of the RSV amount in the SLN 
formulations and the polydispersity indices detected were 
higher. This result was thought to be due to insufficient lipid 
to encapsulate the antioxidizing agent. When the amount of 
lipid was tripled, the SLN system returned to its homogenous 
form with a PI of 0.181. As with the lipid, when the surfactant 
concentrations were tripled, the particle dimensions were 
found to be smaller. In light of these studies, the optimum 
SLN formulation was determined as the RS4 with smaller 
particles in a uniform dispersion.
The ZP of S1 (the SLN formulation without any RSV 
added) was found to be −23 mV ± 0.8. However, the addition 
of RSV decreased the overall charge of the nanoparticles, and 
the ZP was then determined as −15.3 mV ± 0.4. The drug EE 
of RS4 was determined as 73% by a validated HPLC method. 
The production yield was 96%.
NLC formulations were prepared by taking RS4 as the 
starting formulation. Amounts of 5%, 15%, 30%, and 45% of 
the solid lipid were replaced with Miglyol oil in formulations 
coded as RN1, RN2, RN3, and RN4, respectively. Blank 
NLC formulations (N1, N2, N3, and N4) were also studied 
in terms of PS, PI, and ZP.
Surprisingly, the particle dimensions reduced when Miglyol 
was added to the system. The incremental amount of Miglyol 
directly affected the particle size. However, even in that case, the 
Table 2 PS and PI of blank and RSV-loaded SLNs prepared
Code PS (nm) ± SD PI ± SD
S1 174.3 ± 1.8 0.229 ± 0.12
RS1 191.2 ± 3.9 0.580 ± 0.14
RS2 718.1 ± 8.9 0.664 ± 0.02
RS3 287.2 ± 5.1 0.181 ± 0.12
RS4 161.4 ± 2.7 0.263 ± 0.05
Note: Data are presented as mean ± standard deviation (SD).
Abbreviations:  PI,  polydispersity  index;  PS,  particle  size;  RSV,  resveratrol;   
SLNs, solid lipid nanoparticles.
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size of NLCs was smaller than those of the SLNs in all of the 
oil-containing lipid concentrations. The presence or absence of 
RSV did not significantly affect the PS of N1, N2, and N3 for-
mulations. However, the highest level of oil incorporation (45%) 
resulted in a greater PS when compared to blank NLCs.
This result can be explained by the emulsification of the 
system. In our previous study, the heating of the system was 
found to be very important during the melting and mixing 
of the solid lipid.21 It was observed that the lipid base (C 
888) had a tendency to return to solid form during mixing. 
C 888 is a mixture of mono-, di-, and triglycerides. It is well 
known that the longer the fatty acid triglyceride, the greater 
the energy (ie, the higher the temperature) required to convert 
it from a solid to a liquid state. The presence of oil inside 
the NLC system may assist in distributing the heat energy 
more homogeneously. Oils containing a high proportion of 
unsaturated fatty acids are generally liquid, and double bonds 
present in the carbon chain reduce the melting point. This 
may result in more efficient emulsification in NLC systems, 
which in turn has an effect on the size of the droplets formed. 
Upon cooling, pre-emulsion has smaller droplets, which 
may result in smaller nanoparticles. It was reported that the 
broader the spectrum of triglycerides present in the oil, the 
broader the melting range.25
DSC enables an insight into the melting and recrystal-
lization behavior of crystalline materials, such as lipid 
nanoparticles. The breakdown of the crystal lattice by 
heating reveals further information on the polymorphism, 
crystal ordering, eutectic mixtures, and/or the glass transition 
process.26 DSC experiments are useful to understand drug 
and lipid interactions and mixture behaviors such as C 888 
and Miglyol. Therefore, DSC analysis was conducted to 
investigate the melting and crystallization behavior of both 
SLNs and NLCs. The thermograms of blank and loaded 
formulations are shown in Figures 1 and 2.
The melting process for C 888 and RSV took place with 
maximum peaks at 72.31°C and 265.83°C, respectively. It 
was observed that lipid C 888 was completely crystalline 
in SLN as seen in Figure 1. The RSV peak was lost in both 
SLN and NLC formulations, highlighting the solubilization 
of RSV in the lipid phase, as seen in Figure 2. The melting 
point of C 888 in NLC formulations was slightly lower. 
The polymorphism was also determined in prepared NLC 
formulations. In previous studies it was reported that adding 
Miglyol to the carrier depresses the melting point in a 
concentration-dependent manner.27
The ZP of blank NLC did not differ with the amount 
of oil used (P . 0.05). When RSV was loaded, the overall 
charge reduced as in the case of the SLNs. However, the 
lowest electrical charge (highest mV) was observed at an oil 
concentration of 15%. When the RSV-loading capacity was 
compared, the highest EE was obtained at the same concen-
tration (RN2). Thus, it was concluded that encapsulation of 
RSV had an effect on the charge of the NLC system.
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Figure 1 Differential scanning calorimetry thermograms of (a) blank solid lipid nanoparticles; S1 (b) bulk C 888 (c) N2 (d) N3 (e) N4 (f) N1.
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TEM analysis confirmed the colloidal sizes of loaded SLN 
and NLC seen in Figure 3. The regular round shapes of the 
nanoparticles had changed into more amorphous shapes, and 
crystallization of RSV on the surface of SLN could be observed 
in the images. The reason for the settlement  of the drug on the 
surface of the solid lipid matrix – drug-enriched shell model – 
might be explained by the significant difference between the 
melting points of the lipid and the drug. The drug-enriched 
shell model is characterized by the drug located at the interface 
of the lipid and the surfactants, either by fast solidification of 
the lipid matrix, or by the successful competition of the drug 
for the interface due to solubility properties. According to this 
model of drug incorporation, a solid lipid core is formed when 
the recrystallization temperature of the lipid is reached.17,28 
In our study, it was suggested that, once the lipid solidification 
was completed, RSV was pushed to the outside of the lipid 
matrix, without the possibility of being accomodated inside 
the crystallized lipid and instead locating in the outer shell. 
However, we did not observe the same images with NLC. 
Adding liquid oil not only enhanced the loading capacity, but 
may also have altered the model of drug loading. The lipid 
matrix of NLC was shown to solidify upon cooling, but it 
remained in the amorphous state.17 This phenomenon may 
help in hosting RSV in a lipid matrix.
After determination of the optimum amounts of SLN (RS4) 
and NLC (RN2), cell culture studies were conducted to evaluate 
the effect of both the nanoparticle type and also the concentra-
tion of RSV on the fibroblast cell viability (see Figure 4).
Our cell culture studies revealed that at higher concentra-
tions, a dramatic rate of cell death occurred. At the level of 
250 µM, 40% of the cells were dead and at 500 µM, dramatic 
toxicity was observed (P , 0.05). Concentrations below 
50 µM were determined as suitable RSV concentrations for 
both SLN and NLC, as seen in Figure 4. The concentrations 
of 10 µM, 25 µM, and 50 µM were found to be suitable RSV 
concentrations, given the percentage ratio of RSV to fibroblast 
cell vitality. The type of system (SLN or NLC) did not pro-
duce a significant difference in cell cytotoxicity. In a previous 
study, it was reported that the cells remained completely viable 
after exposure to SLN at an RSV   concentration of 100 µM.20 
However, in our study, optimum RSV concentration was 
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Figure 2 Differential scanning calorimetry thermograms of (a) resveratrol, (b) compritol, (c) RN1, (d) RN4, (e) RN2, (f) RS4, (g) RN3.
Table 3 PS, PI, and ZP of NLCs prepared
Code PS (nm) ± SD PI ± SD ZP (mV) ± SD EE%
N1 106.1 ± 1.64 0.292 ± 0.05 −21.7 ± 3.5 –
N2 108.1 ± 0.05 0.288 ± 0.05 −22.3 ± 1.1 –
N3 120.9 ± 0.5 0.241 ± 0.01 −24.3 ± 1.1 –
N4 136.3 ± 1.4 0.221 ± 0.01 −22.0 ± 2.2 –
RN1 90.58 ± 1.7 0.280 ± 0.06 −16.1 ± 0.1 82
RN2 110.5 ± 1.3 0.259 ± 0.01 −13.8 ± 0.1 91
RN3 117.3 ± 1.6 0.224 ± 0.03 −15.2 ± 0.6 72
RN4 148.7 ± 1.5 0.213 ± 0.01 −16.3 ± 0.08 78
Note: Data are presented as mean ± SD standard deviation (SD).
Abbreviations: EE, entrapment efficiency; PI, polydispersity index; PS, particle size; 
ZP, zeta potential; NLCs, nanostructured lipid carriers.
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determined to be 50 µM for both SLN and NLC, since the 
highest viability was obtained at this concentration.
Figure 5 represents the number of cells versus fluorimetric 
intensity. The peaks are the results of ROS produced inside the 
cells, and this production is expressed as additional fluorescence. 
Thus, the higher the fluorescence, the lower the antioxidant 
effect. The concentration of DCFH-DA was chosen as 1 mM in 
order to differentiate between ROS fluorescence and noise.
Figure 6 represents the histogram number of cells versus 
fluorimetric intensity evaluated for RSV , RSV-loaded SLN 
and NLC, control, and H2O2-treated samples.
Furthermore, the morphologic parameters of the cell 
substrates treated with SLN and NLC samples demonstrated 
that they were viable (Figure 7), indicating that the oxidative 
damage did not cause cell death. The fluorescence intensity is 
directly related to ROS production due to the oxidative damage 
caused by H2O2 treatment. The higher the fluorescence, the 
higher the concentration of   intracellular ROS. The cell sub-
strate treated with H2O2 showed the highest ROS accumulation, 
as indicated by the cell peak characterized by fluorescence 
intensity ranging from 10–100 au. The control cell substrate 
had the lowest ROS accumulation; all the cells counted pre-
sented a fluorescence intensity of below 10. The cell substrates 
treated with RSV alone or loaded in the colloidal systems 
had cell fluorescence intensities below that of the substrate 
treated with H2O2 alone.
This indicates that the presence of RSV , either alone or 
loaded in the colloidal systems will decrease ROS accumula-
tion and accordingly exert antioxidant activity. These results 
are in agreement with integration values of % fluorescence 
intensity vs cell counted curve calculated in the range of 
10%–100% fluorescence intensity for the samples (Figure 7). 
RSV alone and both the RSV-loaded colloidal systems were 
characterized by a fluorescence intensity below that of the 
substrate treated with H2O2 alone (P , 0.05).
Generally, antioxidant molecules are inherently unstable 
in nature and are susceptible to photodegradation in the pres-
ence of oxygen, which makes them difficult to formulate into 
an acceptable, stable product for dermal application.29 The 
stability of chemical labile hydrophobic antioxidants like 
retinol, Coenzyme Q10, alpha-lipoic acid, beta-carotene, 
and alpha-tocopherol could be enhanced when incorporating 
them into lipid nanoparticles.30–32 Thus, the encapsulation 
of RSV into a lipid nanosystem might also be helpful in 
improving stability, whilst performing a protective effect as 
sufficiently as the RSV molecule itself.
The mean fluorescence intensity percentage results 
obtained from cytofluorimetry studies could be listed in 
order as: RSV (31.17) . RSV-SLN (32.06) . RSV-NLC (30.69) . 
Control (28.77). RSV-loaded NLC showed a percentage value 
of fluorescence below those of RSV and RSV-loaded SLN, 
indicating less ROS production, although this was not 
statistically significant. This result could be due to both PS 
and ZP, in that smaller dimensions of RSV-loaded NLC with a 
reduced negative electrical charge should favor NLC fibroblast 
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Figure 3 Transmission electron microscopy images of (A) resveratrol (RSV)-loaded solid lipid nanoparticles (SLN) (S4) (B) RSV-loaded nanostructured lipid carriers (NLC) (RN2).
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endocytosis. In fact, it is well known that reducing the 
anionic charge on nanoparticle carriers increases nonspecific 
interactions with cell surfaces.33 This was also demonstrated 
in cytofluorometry studies by Hayes et al, where positively 
charged nanoparticles were shown to have a tendency to bind 
to cell surfaces and become endocytosed.34
Ex vivo skin diffusion studies were also conducted to 
analyze the diffusion and skin accumulation of RSV . Under 
the conditions of our study, after 24 hours, no RSV could be 
detected in the receptor phase (ethanol and water at a ratio 
of 1:1) with both SLN and NLC. Given that there was no 
transport of RSV into the receptor phase of Franz diffusion 
cells, it was thought that encapsulation of RSV into SLN or 
NLC might have improved the accumulation of RSV into 
the skin. Therefore, the skin samples were homogenized, and 
the accumulation of RSV was investigated (see Figure 8).
30
20
10
C
o
u
n
t
C
o
u
n
t
C
o
u
n
t
C
o
u
n
t
C
o
u
n
t
0
80
60
40
20
0
30
20
10
0
100 101 102 103 100 101 102 103
30
20
10
0
40
30
20
10
0
100 101
FL1 INT
RSV RSV-SLN RSV-NLC
H2O2 Control
FL1 INT FL1 INT
FL1 INT FL1 INT
102 103 101 100 102 103 101 100 102 103
Figure 5 Signal intensity histograms of cells incubated with resveratrol (RSV), RSV-loaded solid lipid nanoparticles (SLN) (RS4) nanostructured lipid carriers (NLC) (RN2), 
control and H2O2-treated samples.
1000
800
600
400
200
0
1000
800
600
400
200
0
0 200 400 600 800 1000 0 200 400
FS INT
RSV-SLN RSV-NLC
FS INT
S
S
 
I
N
T
S
S
 
I
N
T
600 800 1000
Figure 6 Morphologic parameter of fibroblasts treated with solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) samples.
Abbreviation: RSV, resveratrol.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1848
Gokce et alInternational Journal of Nanomedicine 2012:7
RSV could be extracted from nanoparticle-treated skin 
samples (SLN: 1.55 ± 0.13 µg/cm2, NLC: 1.99 ± 0.17 µg/cm2). 
This phenomenon of RSV accumulation in the skin could be 
explained by the lipid characteristics of both the SLN and 
NLC systems, and in particular by the lipid-to-water partition 
coefficient of RSV . As observed in our previous study con-
ducted with cyclosporine A incorporated SLNs, when the 
log P of the drug was high, enzymatic degradation (namely 
lipase degradation) should occur, and the drug would be 
released in situ.21 Since the logP of RSV is approximately 3,35 
it was preferentially partitioned in the lipid phase of the 
nanoparticles, irrespective of the nanoparticle type.
However, the accumulation of RSV in both dermis and 
epidermis showed significant differences depending on nano-
particle type. Dermis accumulation was more significant for 
NLC; however, more epidermal accumulation was observed 
with SLN (see Figure 8). The difference between epidermis 
and dermis accumulation indicated that the most likely site of 
accumulation might be the the appendages of the skin, such 
as hair and glands, where the nanostructure could enter until 
the complete degradation of the structure had occurred, as has 
previously been shown for lecithin/chitosan nanoparticles.24 It 
was thought that smaller PS with the correspondingly reduced 
electrical charge helped the penetration of the NLCs to deeper 
layers of skin tissue.
Conclusion
RSV-loaded SLN and NLC have been prepared by means 
of the high shear homogenization method. Compritol C888 
(for both SLN and NLC) and Miglyol 812 (for NLC alone) 
were used as the lipid phase. The optimal SLN and NLC 
formulations were based on a 60:1 lipid-to-drug ratio. In the 
NLC system, the optimal liquid lipid concentration was 15% 
of the whole lipid phase (Compritol and Miglyol).
Both RSV-loaded SLN and NLC systems were character-
ized by high biocompatibility, with normal human dermal 
fibroblasts at a concentration of 50 µM of RSV. At this 
concentration, RSV loaded in both the colloidal systems 
was effective in decreasing ROS accumulation exerting 
antioxidant activity.
Ex vivo skin diffusion studies showed that RSV was unable 
to permeate skin tissue. However, both systems permitted 
the penetration/accumulation of RSV into skin. NLC was 
characterized by better performance, indicating that NLC 
had a noticeably higher tendency to penetrate into skin with 
respect to SLN. In particular, NLC demonstrated better der-
mis accumulation, which could be determined by smaller PS 
and lower ZP, favoring particle penetration and possibly cell 
endocytosis.
The NLC formulation containing 255 mg of Compritol 
and 45 mg of Mygliol (15% of the lipid phase) was the 
most promising formulation. In particular, it demonstrated a 
fibroblast protection against intracellular ROS accumulation, 
and was suitable for the delivery of RSV , enhancing drug 
penetration/accumulation into the skin. Further studies will 
be undertaken to evaluate in vivo efficacy.
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